ORIGINAL ARTICLE
Year : 2017 | Volume
: 30 | Issue : 3 | Page : 706--714
Vitamin D receptor polymorphisms as predictors of response to interferon/ribavirin-based therapy in Egyptians with chronic hepatitis C infection
S Shoeib1, H Zaghla2, S Dina3, M Abd El Hafez1, A Efat1, A El Shormilisy4, R Mohamed5 1 Department of Internal Medicine, Faculty of Medicine, Mernoufia University, Mernoufia, Egypt 2 Department of Hepatology, National Liver Institute, Mernoufia University, Mernoufia, Egypt 3 Department of Medical Biochemistry, Faculty of Medicine, Cairo University, Cairo, Egypt 4 Department of Internal Medicine, Faculty of Medicine, Helwan University, Helwan, Egypt 5 Department of Internal Medicine, Suez Canal Authority Hospital, Ismailia, Egypt
Correspondence Address:
R Mohamed Suez Canal Authority Hospital Egypt
Objective
The aim of the present study was to assess the influence of polymorphisms in vitamin D receptors (VDRs) Fok1 and Apa1 and interleukin 28B rs12979860 C/T on the response to interferon/ribavirin-based therapy in Egyptians with chronic hepatitis C.
Background
Vitamin D exerts immunomodulatory effects on the host response against infection with hepatitis C virus. Genetic polymorphisms affecting the VDR gene have been implicated in several immune disorders.
Patients and methods
This retrospective study was conducted on 80 patients who were divided into two groups: group I – the nonresponders group – comprised 40 patients and group II – the sustained virological response (SVR) group – also comprised 40 patients. The present study also included 20 healthy volunteers as controls. Two single nucleotide polymorphisms in VDRs Fok1 and Apa1 and in IL28B rs12979860 C/T) were determined by real-time PCR and restriction fragment length polymorphisms.
Results
Genotypes of IL28B rs12979860 (CC/CT/TT) were found in 23 (57.5%), 15 (37.5%), and two (5%) patients and of Apa1 (CA/AA/CC) in 24 (60%), 14 (35%), and two (5%) patients. Genotypes of Fok1 (TT/CC/TC) were found in 23 (57.5%), nine (22.5%), and eight (20%) patients, respectively, in the SVR group. Regarding IL28B rs12979860 polymorphisms, patients with a T-allele carrier had higher frequency among nonresponders (87.5%) in comparison with SVR (42.5%). Regarding VDR (Fok1) polymorphisms, patients with a C-allele carrier had higher frequency among nonresponders (92.5%) in comparison with SVR (42.5%). Regarding VDR Apa1 polymorphisms, patients with a C-allele carrier had higher frequency among nonresponders (92.5%) in comparison with SVR (65%).
Conclusion
Pretreatment vitamin D level was significantly higher in responders, and this can be used as a predictor of response to combination therapy for hepatitis C virus. VDR gene polymorphisms (Fok1 and Apa1) and IL28B rs12979860 polymorphism are independently related to response to interferon/ribavirin-based therapy in chronic hepatitis C.
How to cite this article:
Shoeib S, Zaghla H, Dina S, El Hafez M A, Efat A, El Shormilisy A, Mohamed R. Vitamin D receptor polymorphisms as predictors of response to interferon/ribavirin-based therapy in Egyptians with chronic hepatitis C infection.Menoufia Med J 2017;30:706-714
|
How to cite this URL:
Shoeib S, Zaghla H, Dina S, El Hafez M A, Efat A, El Shormilisy A, Mohamed R. Vitamin D receptor polymorphisms as predictors of response to interferon/ribavirin-based therapy in Egyptians with chronic hepatitis C infection. Menoufia Med J [serial online] 2017 [cited 2024 Mar 29 ];30:706-714
Available from: http://www.mmj.eg.net/article.asp?issn=1110-2098;year=2017;volume=30;issue=3;spage=706;epage=714;aulast=Shoeib;type=0 |
|